Latest Tyrosine kinase inhibitors Stories
EAST HANOVER, N.J., Feb.
Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally cost-effective.
WALTHAM, Mass., Feb.
CAMBRIDGE, Mass., Feb.
Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth.
A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract.
The interaction of enzymes â€“ especially the tyrosine kinases called Src and inducible nitric oxide synthase â€“ plays an important role in the growth of non-small cell lung cancers, the most common form of this deadly disease in the United States, said researchers from Baylor College of Medicine in a report in the Journal of Biological Chemistry.
Team cautions that results are very preliminary and they cannot yet rule out other reasons for success.
The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team scientists to discover a compound capable of halting a common type of drug-resistant lung cancer.
Panel Votes Against Approval of Tarceva(R) as Maintenance Drug WASHINGTON, Dec. 17 /PRNewswire-USNewswire/ -- Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients.
- An imitative word; an onomatopoetic word.